Meeting
2021 ASCO Annual Meeting
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
Authors
Cristina Suarez Rodriguez
Vall d' Hebron University Hospital, Barcelona, Spain
Cristina Suarez Rodriguez , James Larkin , Poulam M. Patel , Begoña P. Valderrama , Alejo Rodriguez-Vida , Hilary Glen , Fiona Thistlethwaite , Christy Ralph , Gopalakrishnan Srinivasan , Maria Jose Mendez-Vidal , Abigail Carter , Charlotte Tyson , Aaron Prendergast , Kelly Mousa , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02819596
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4511)
DOI
10.1200/JCO.2021.39.15_suppl.4511
Abstract #
4511
Abstract Disclosures
Similar Posters
First Author: Francesca Jackson-Spence
Poster
2017 ASCO Annual Meeting
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
First Author: Robert L. Ferris
Poster
2017 ASCO Annual Meeting
Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).
First Author: Noah M. Hahn
Poster
2023 ASCO Annual Meeting
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
First Author: Bernard Doger de Spéville